|Salary:||Up to £45,000|
|Placed On:||24th May 2022|
|Expires:||23rd July 2022|
Position Summary DefiniGEN are seeking an experienced, highly motivated individual to lead the company’s liver disease model development programme.
DefiniGEN were founded in 2013 as a spin-out from Cambridge University. We use a patented differentiation process in combination with in-house gene editing to differentiate human induced Pluripotent Stem Cells (iPSC) to hepatocytes which are then used to support our client’s work in developing next generation liver therapeutics. Typically we generate models of liver disease using our technology and screen client therapeutics for activity using our in-house phenotyping capability. As our business expands we are seeking to develop further disease models and supporting bioassays and are seeking an experienced scientist who can lead and drive this critical business function.
This position will have two key functions within the business. Firstly you will lead the development of DefiniGEN’s future portfolio of hepatocyte disease models and supporting phenotypic endpoints. Secondly you will be a key knowledge resource within the organisation for scientists conducting phenotypic screening and for our sales team in client and project on-boarding meetings. Therefore, expertise in iPSC-derived disease models and their characterisation is essential for this position.
The delivery of new disease models and the conduct of client projects will be pivotal to the success of this role. Furthermore, DefiniGEN’s core business is using cell-based bioassay to demonstrate the potency of client-supplied compounds. Typically these assays are bespoke and require significant scientific input in terms of assay design, conduct and data interpretation. The post holder will be expected to have full scientific oversight for the design and conduct of these studies and the interpretation of the resulting data to ensure maximum value to our clients.
Key Roles and Responsibilities
E – Essential, D - Desirable
Type / Role: